Hanson R N, Davis M A, Holmar B L
J Nucl Med. 1980 Sep;21(9):846-51.
Three new iodobenzoyl derivatives of acebutolol, a cardioselective beta antagonist, were synthesized and labeled with iodine-125. The biodistributions of these labeled compounds were determined in normal rats and compared with that of thallium-201. Fifteen minutes following i.v. administration, the iodine-125-labeled meta- and para-iodobenzoyl acebutolols possessed the greatest ventricular uptake and the highest ventricle-to-blood and ventricle-to-lung ratios of the new agents. The corresonding values for thallium-201 were 2.5 to 3.0 times as high. The data in this study suggest that more lipophilic derivatives of the cardioselective beta antagonists will possess increased uptake and cardioselectivity, and thereby will compare more favorably with thallium-201 as myocardial imaging agents.
合成了三种新的醋丁洛尔(一种心脏选择性β受体拮抗剂)的碘苯甲酰衍生物并用碘 - 125进行标记。在正常大鼠中测定了这些标记化合物的生物分布,并与铊 - 201的生物分布进行了比较。静脉注射给药15分钟后,碘 - 125标记的间碘苯甲酰醋丁洛尔和对碘苯甲酰醋丁洛尔在新制剂中具有最大的心室摄取量以及最高的心室与血液和心室与肺的比率。铊 - 201的相应值高2.5至3.0倍。本研究中的数据表明,心脏选择性β受体拮抗剂的亲脂性更强的衍生物将具有更高的摄取量和心脏选择性,从而作为心肌显像剂与铊 - 201相比将更具优势。